Treatment with anti-FasL mAb starting at 11 days after infection, but not anti-TNF or anti-TRAIL antibodies, protect CD8 T cells from AICD, improved cytokine production by CD4 T cells, activate CD8 T cells, upregulate Fas expression by CD8 T cells earlier than CD4 T cells, and decreased parasitemia (22). The gene discussed is FASLG; the disease is infection.